348640-06-2

Basic information

• Product Name: 4-Bromo-7-azaindole
• Synonyms: 1H-PYRROLO[2,3-B]PYRIDINE, 4-BROMO-;4-BROMO-7-AZAINDOLE;4-BROMO-1H-PYRROLO[2,3-B]PYRIDINE;4-broMo-1H-pyrrolo[2;4-BroMo-7-Azaindol;4-Bromo-1H-pyrrolo-[2,3]pyridine;348640-06-2
• CAS NO: 348640-06-2
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• EINECS: 1592732-453-0
• Product Categories: CHIRAL CHEMICALS;Azaindoles;6
• Mol File: 348640-06-2.mol
• Article Data: 19

Chemical Properties

• Melting Point: 178-183℃
• Appearance: Yellow to orange/Solid
• Density: 1.771 g/cm³
• Refractive Index: 1.728
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 12.95±0.40(Predicted)
• CAS DataBase Reference: 4-Bromo-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-7-azaindole(348640-06-2)
• EPA Substance Registry System: 4-Bromo-7-azaindole(348640-06-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 348640-06-2(Hazardous Substances Data)

Usage

Description

4-Bromo-7-azaindole is an organic compound characterized by its pale yellow powder form. It is a significant building block in the synthesis of various substituted azaindole products, which are essential in the development of pharmaceuticals and other chemical compounds.

Uses

Used in Pharmaceutical Industry:
4-Bromo-7-azaindole is used as an important organic intermediate for the synthesis of substituted azaindole products. These products are crucial in the development of new pharmaceuticals, particularly those targeting specific biological pathways or receptors.
Used in Chemical Synthesis:
4-Bromo-7-azaindole is used as a chemical reagent in the synthesis of tyrosine kinase inhibitors. Tyrosine kinase inhibitors are a class of drugs that block the activity of tyrosine kinases, which are enzymes involved in cell signaling and growth. These inhibitors are used to treat various types of cancer by preventing the uncontrolled growth of cancer cells.

InChI:InChI=1/C7H5BrN2/c8-6-2-4-10-7-5(6)1-3-9-7/h1-4H,(H,9,10)

Upstream product

• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 271-63-6 7-Azaindole 
• 7143-01-3 Methanesulfonic anhydride 

Downstream Products

• 1067887-43-7 phenyl(1H-pyrrolo[2,3-b]pyridin-4-yl)methanol 
• 1310556-83-2 3-fluoro-6-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-(phenylsulfonyl)-1H-indazol-4-amine 
• 1310556-82-1 6-[2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1-(phenylsulfonyl)-1H-indazol-4-amine 
• 1310556-78-5 N-{1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-indazol-4-yl}-2-furancarboxamide 
• 1198438-12-8 2-(chloromethyl)-N-{1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-indazol-4-yl}-1,3-thiazole-4-carboxamide 
• 1198438-14-0 1-(phenylsulfonyl)-6-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-indazol-4-amine 
• 1014613-05-8 1-(benzenesulfonyl)-4-bromo-2-methyl-1H-pyrrolo[2,3-b]pyridine 
• 1248587-58-7 3-(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperazin-1-yl)phenol 
• 1253410-44-4 4-methyl-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenylamine 
• 1234616-25-1 4-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine 
• 942920-26-5 4-[1-{[4-(methyloxy)phenyl]methyl}-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine 
• 942920-30-1 [3-(4-nitrophenyl)-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl]acetic acid 
• 942919-32-6 4-[3-(4-nitrophenyl)-1-(2-propen-1-yl)-1H-pyrazol-4-yl]-1Hpyrrolo[2,3-b]pyridine 
• 942919-30-4 4-[1-(1,1-dimethylethyl)-5-(4-nitrophenyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition

A solution-phase parallel synthesis of triazole-derived ruxolitinib analogues was developed in the current study. The method employs copper-catalyzed azide-alkyne cycloaddition to build up the central triazole template. Product isolation by precipitation

CHEMICAL COMPOUNDS

There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.